US-based medical device firm ClearFlow has reported positive results from the Prevention of Retained Blood Outcomes Using Active Clearance Technology trial (PRO-ACT) a clinical trial evaluating the use of PleuraFlow System to prevent retained blood complications.

The PleuraFlow system allows caregivers to actively keep chest drainage tubes clear of clots immediately after heart surgery.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial evaluated the efficacy of the protocol for actively clearing chest tubes of clotted blood to prevent retained blood complications.

A primary outcome of the trial included less interventions for retained blood complications after heart surgery and prior to discharge.

"The PleuraFlow system allows caregivers to actively keep chest drainage tubes clear of clots immediately after heart surgery."

ClearFlow founder and chairman Ed Boyle said: "Chest tube clogging is known to occur in over one-third of heart surgery patients in the early hours after heart surgery, and nearly one in five can have some form of retained blood complication that includes the need to perform subsequent invasive reinterventions to remove undrained blood or clots from inside the chest after heart surgery."

See Also:

Klinikum Nürnberg Heart Center study principal investigator Dr Theodor Fischlein has presented the results at the Cardiovascular-Thoracic (CVT) Critical Care 2014 annual meeting. The meeting was organised by the Foundation for the Advancement of CardioThoracic Surgical Care (FACTS-Care) in Washington, DC.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The results showed a significant reduction of interventions for retained blood complications by 42% in the treatment group and also of postoperative atrial fibrillation (POAF).

According to the company, patients treated with PleuraFlow System had a statistically significant reduction in bleeding, suggesting that the Active Clearance Technology may help reduce the amount of bleeding following heart surgery.

The company’s PleuraFlow System with Active Clearance Technology is approved for use in the US, Europe, Australia, Brazil and Canada.

The system has either been cleared or is pending clearance in other countries.